Phase 4
Completed N=59
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Workplace Migraine Treatment
Source: ClinicalTrials.gov NCT01086358 ↗
Enrolled (actual)
59
Serious AEs
0.0%
Results posted
May 2018
Primary outcomePrimary: Workplace Productivity and Activity Impairment Scale (WPAI). — 4.15; 2.44 hours — p=0.007
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet.
During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. The subjects will complete questionnaires after treating each migraine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Workplace Productivity and Activity Impairment Scale (WPAI). |
4.15; 2.44 | 0.007 sig |
| SECONDARY Lost Workplace Productivity |
2.25; 1.23 | 0.010 sig |
| SECONDARY Lost Activity Time |
1.89; 1.22 | 0.059 |
| SECONDARY Favorable Response on Migraine-ACT |
46; 71 | 0.016 sig |
Eligibility Criteria
Inclusion Criteria
- episodic migraine diagnosis
- age 18 or older
- currently using a triptan as primary migraine monotherapy
- currently employed
- if of childbearing potential, willing to prevent pregnancy during study participation
- able to understand and consent to study participation
Exclusion Criteria
- younger than age 18
- not having episodic migraine diagnosis
- not using a triptan as primary migraine monotherapy
- not currently employed
- pregnant or nursing or unwilling to prevent pregnancy during study participation
- unable to understand and consent to study participation
Data sourced from ClinicalTrials.gov (NCT01086358). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.